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Abstract
Objectives: To assess whether switching patients with suboptimally controlled pulmonary arte-
rial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk
test (6MWT) distance and World Health Organization functional class.
Methods: This was a retrospective cohort analysis of 37 patients from a single center. Patients
were separated into three heterogeneous treatment groups and followed for 18 months: switch
group (n¼ 14): patients switched to macitentan from bosentan/ambrisentan; added group
(n¼ 11): patients who began macitentan as de novo therapy (n¼ 5) or who added macitentan
to an existing sildenafil regimen (n¼ 6); and control group (n¼ 12): patients for whom sildenafil
and/or bosentan/ambrisentan therapy was unchanged.
Results: Mortality was observed in two patients (one each, switch and added groups). Patients in
the control group had one hospital admission and 100% survival. There was significant improve-
ment in functional class for the switch and added groups. Statistically significant improvement was
observed in 6MWT distance in the added group alone. Overall, 92% of patients continued
macitentan throughout the study.
Conclusion: Macitentan was well tolerated. For bosentan/ambrisentan-treated patients with
suboptimally controlled pulmonary arterial hypertension, switching to macitentan may facilitate
an improvement in functional class.
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Introduction
Pulmonary hypertension (PH) is associated
with impaired quality of life, poor function-
al capacity, reduced survival, and mean
pulmonary artery pressure (mPAP)
 25mmHg at rest.1 There are five types
of PH.2,3 Pulmonary arterial hypertension
(PAH), a rare form of PH, comprises
PAPm  25mmHg, combined with pulmo-
nary capillary wedge pressure  15mmHg.3
PAH affects pulmonary circulation, but can
occur secondary to other medical condi-
tions.3 The Armadale PH study suggested
a prevalence of 15/100,000 people with
PAH in a Western Australian population.4
Traditionally, patients with PAH have had
very high morbidity and mortality.5
However, the prognosis of PAH has
improved with the advent of targeted
PAH therapies.4
The World Health Organization (WHO)
categorizes PH into four classes of function-
al limitation: I (nil) to IV (severe).2 Patients
with WHO functional Class II and higher
are generally eligible for targeted therapies,5
including endothelin-1 receptor antagonists
(ERAs), phosphodiesterase-5 inhibitors
(PDE5) and synthetic prostacyclin/prosta-
glandin analogs.6 Other therapies include
prostanoid receptor agonists.7 A recent
meta-analysis showed that therapy with
prostacyclin, an ERA, or a PDE5 inhibitor
improved mortality, compared with con-
trols.8,9 Nonetheless, morbidity and mortal-
ity from PAH remain high.
In September 2014, a new ERA—maci-
tentan—was made available under the
Pharmaceutical Benefits Scheme in
Australia.10 Macitentan demonstrates
enhanced receptor binding, potency, and
receptor occupancy half-life, compared
with other ERAs.8 Thus, macitentan may
be superior to either ambrisentan or bosen-
tan for treatment of PAH. Compared with
placebo, participants on macitentan have
shown improved exercise capacity and
WHO functional class;11 macitentan signif-
icantly reduced morbidity and mortality,
even among patients who received maciten-
tan as an addition to established PAH ther-
apy.12 There is no notable increase in the
risk of hepatotoxicity or peripheral edema
on macitentan.13 Despite these theoretical
benefits of macitentan, to our knowledge,
no studies have directly compared maciten-
tan with other available ERAs, or any other
targeted therapies. Thus, an analysis is
needed to determine whether a switch of
ERAs to macitentan is associated with
functional improvement in patients with
suboptimal response to first-line therapy.
We hypothesized that in adult patients
with clinician-determined suboptimal
response to bosentan or ambrisentan, a
switch to macitentan would be associated
with improved outcomes as measured by
WHO functional class, six-minute walk
test (6MWT), and echocardiographic
parameters as well as reduced number of
hospitalizations, irrespective of concurrent
PDE5 inhibitor use. Furthermore, we
hypothesized that drug tolerability would
be improved in patients switched
to macitentan.
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Materials and methods
Study design
Ethics approval was granted through a low-
risk application to the Human Ethics
Research Committee through the
University of Notre Dame Australia. This
retrospective cohort study involved the
analysis of cardiopulmonary, clinical, and
exercise parameters from the records of
patients who underwent treatment for
PAH by one clinician in a private clinic in
Australia. A public notification was posted
in the examination rooms of the clinic to
notify patients of the study.
The patients were classified into
three treatment groups (described in
“Participants” subsection, below) based on
treatment status, which was determined
prior to the study. The treating clinician
used a combination of objective measures
to determine which patients were stable
and which patients showed a lack of
response to first-line therapy; these included
WHO functional class, 6MWT distance,
echocardiography, tolerance to medication,
and hospitalization requirement. Patients
were then allocated to the appropriate
treatment groups.
Data were retrospectively collected from
patient records for the period from January
2014 through September 2016. All data
reflected conventional clinical practice
and clinical management decisions, which
were not impacted by the current
study. Patients with either prevalent
(length of diagnosis  6months) or incident
(length of diagnosis< 6months) PAH
were included.
Participants
Records of patients 18 years of age who
were diagnosed with Group 1 PH (i.e.,
PAH), and who were eligible for
Pharmaceutical Benefits Scheme-subsidized
targeted therapies, were included in the
study. For the purpose of analysis, patients
were divided into three groups based upon
management decisions. The treating clini-
cian made these decisions prior to begin-
ning any research with regard to treatment
of the patients.
The group of interest (switch group) con-
sisted of patients who were switched from
bosentan or ambrisentan, based on the
clinician’s assessment of subopti-
mal response.
The first comparator group (added
group) consisted of patients who began
macitentan as first-line therapy or who
added macitentan therapy to existing sil-
denafil therapy.
The second comparator group (control
group) consisted of patients who were
judged by the treating clinician to have
stable PAH; in these patients, therapy
with sildenafil and/or bosentan/ambrisen-
tan was unchanged.
Variables
In addition to survival data, information
was collected from all patient records
regarding demographic variables (age,
sex), clinical diagnosis (type of PAH), and
duration since diagnosis. Both WHO func-
tional class and the 6MWT distance in
meters were recorded as functional out-
comes. Furthermore, the following echocar-
diography measures were recorded for each
patient: right ventricular size, right ventric-
ular systolic function, and pulmonary
artery systolic pressure (PASP). The fre-
quencies of all-cause hospitalization and
mortality were recorded, as were the inci-
dences of all known side effects of maciten-
tan and other ERAs (e.g., abnormal liver
function tests, gastrointestinal upset, and
anemia). The use of other therapies, includ-
ing diuretics, was also noted.
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Data analysis
Demographic data (de-identified) for all
patients were recorded in an Excel spread-
sheet and coded appropriately. Stability of
PAH was determined via the analysis of the
outcome measures listed in variables.
Differences among groups were identified
using analyses of variance and analyses of
covariance for continuous variables. Post
hoc analyses involving small sample num-
bers and repeated measures data were per-
formed using Friedman’s nonparametric
test for related samples. The nonparametric
Wilcoxon signed-rank test was used to com-
pare changes in categorical rank data.
Measures of association for categorical
data were tested using chi-squared analyses.
SPSS for Windows (version 25.0.0.1; IBM
Corp., Armonk, NY, USA) was used to
perform statistical comparisons. A p-value
of < 0.05 was considered to be significant.
Missing data were addressed as follows.
Initially, all demographic information was
collected. If information regarding 6MWT
was unavailable, this parameter was left
blank. For patients with insufficient tricus-
pid regurgitation, no numerical value was
assigned for PASP. Regarding echocardiog-
raphy, some reports did not describe systol-
ic function and size; thus, this information
was coded as absent. Patients who had
missing data were excluded from analyses
involving those parameters.
Results
This exploratory study enrolled a conve-
nience sample of 37 patients, which is con-
siderable for a rare disease. All had PAH
confirmed by right heart catheterization.
Non-PAH causes of pre-capillary PH were
excluded, based on known diagnostic and
assessment protocols.1 There were 14
patients in the switch group, 11 patients in
the added group, and 12 patients in the con-
trol group. One patient each in the switch
and added groups died. The three groups
were similar in age, sex distribution, and
type of PAH (Table 1).
Regarding WHO Functional Class,
Figure 1 shows the changes in actual rank
for each patient. Wilcoxon signed rank test
between functional class at baseline and at
6months showed significant changes for the
switch (z¼2.91, p¼ 0.004) and added
Table 1. Demographic characteristics.
Switch (n¼ 14) Added (n¼ 11) Control (n¼ 12) p-value
Age (years, SD) 63 13 65 5 74 9 0.114
Female sex (%) 86% 73% 83% 0.927
PAH etiology 0.818
Idiopathic 64% 55% 67%
Scleroderma 36% 45% 33%
PAH type Not compared
Incident 3 8 2
Prevalent 11 3 10
Prior medication Not compared
Bosentan 12 0 9
Ambrisentan 2 0 0
None 0 5 0
Sildenafil 0 6 1
Bosentanþ sildenafil 0 0 2
SD, standard deviation; PAH, pulmonary arterial hypertension.
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groups (z¼2.12, p¼ 0.03), but not for the
control group (z¼ 0.00). For 6MWT
(Table 2), by 6months there was a 37-m
improvement in the switch group (not sta-
tistically significant), a 98-m improvement
in the added group (p¼0.01), and no signif-
icant change in the control group. There
was no difference between the switch and
control groups, whereas there was a differ-
ence between the added and control groups
(p¼ 0.03). There was weak statistical evi-
dence for a difference between the switch
and added groups (Figure 2).
Given the small study numbers, a
Friedman’s statistic was calculated to deter-
mine whether echocardiography scores dif-
fered among the three measurement points
for each group. The v2 test did not show
significant differences in right ventricular
size or right ventricular systolic function
for any of the groups (Figures 3 and 4).
PASP at echocardiography was only
recorded for patients with sufficient tricus-
pid regurgitation (Figure 5). In the switch
group, eight patients at baseline had insuf-
ficient tricuspid regurgitation; thus, no data
were available for analysis in these patients.
Similarly, two patients in the control group
and one patient in the added group had
insufficient tricuspid regurgitation and


















































Figure 1. World Health Organization functional class. WHO, World Health Organization; 6m, 6months.
Table 2. Six-minute walk test distance.
Group Time point
Distance
(m, mean SD) p-value
Switch Baseline 371 28 0.17
3 months 415 29
6 months 404 42
Added Baseline 334 28 0.01
3 months 393 29
6 months 415 42
Control Baseline 484 28 0.88
3 months 464 29
6 months 461 42
SD, standard deviation.
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Figure 2. Mean six-minute walk test distance in meters.
Figure 3. Echocardiography analysis of right ventricular systolic function. 6m, 6months; Mild-Mod, mild to
moderate dysfunction.
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statistically significant difference in PASP
for the switch (v2¼ 3.5), added (v2¼ 1.6),
and control groups (v2¼ 2.1).
Eleven patients had at least one hospital
admission. Mortality was 2/37 (one each in
the switch and added groups) with an annu-
alized mortality of 3.6%. Patients in the con-
trol group remained stable with one hospital
admission and 100% survival. Overall, 92%
of patients continued macitentan throughout
the study. One patient in the switch group
stopped macitentan due to anemia; another
patient in the switch group stopped all ther-
apy, received palliative therapy, and died
shortly thereafter (Table 3).
Discussion
This study found that, in ERA-treated
patients who did not show well-controlled
PAH (based on WHO Functional Class,
6MWT distance, and echocardiography
features of right ventricular failure), switch-
ing to macitentan was associated with a sta-
tistically significant improvement in
functional class. These findings confirmed
that macitentan is well tolerated and effec-
tive for treatment of PAH.
There was an improvement in the WHO
functional class in the switch group.
Notably, the WHO functional class is a
robust measure and has been used to
guide therapy.3,14,15 To our knowledge this
is the first study to show an improvement in
WHO functional class following a switch
from an existing ERA regimen to maciten-
tan. Additionally, the 6MWT is a widely
used, simple, and non-invasive test that
measures reduced exercise capacity and
provides an estimate of aerobic fitness in
patients with PAH.2,15 In this study, there
was a 37-m improvement in the 6MWT dis-
tance in patients who switched to maciten-

















































Figure 4. Echocardiography analysis of right ventricle size. 6m, 6months.
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who remained on their previous therapy;
however, this improvement was not statisti-
cally significant.
Echocardiographic assessment of right
ventricular function is routine for disease
monitoring; however, its value in following
patients—to determine response to thera-
py—has not been established.16–18 Our find-
ings also showed no clear value of right
ventricular function for determining
Figure 5. Mean echocardiography analysis of pulmonary artery systolic pressure. PASP, pulmonary artery
systolic pressure.
Table 3. Frequency of side effects for each group at 6 months*.
Switch (n¼ 14) Added (n¼ 11) Control (n¼ 12)
Discontinued drug due to side effects 1 0 0
Stopped or changed medication 2 0 1
Side effects
GIT 0 0 0
Liver derangement 2 2 2
Anemia (Hemoglobin< 100) 2 3 1
New treatment required
Diuretics 4 6 2
Hospitalizations 5 4 2
Mortality† 1 1 0
†Both patients who died were World Health Organization functional Class IV at baseline.
*Because of the small numbers of reported side effects, no data analysis was performed using data shown in this table.
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response to therapy: there were no measur-
able differences in the switch or added
groups with regard to right ventricular sys-
tolic function or size, nor were there differ-
ences in PASP. Clinicians should exercise
caution in the use of echocardiography for
monitoring disease progression; further
investigation is needed regarding non-
invasive assessments of disease in patients
with PAH.13,19
This study had several limitations. Most
importantly, it was retrospective and some
data were missing. Furthermore, the sample
size was relatively small, such that it was
not powered to determine differences in
mortality. Notably, mortality and hospital-
izations for PAH occurred only in
macitentan-treated patients. This was
expected, as these groups contained patients
who had shown poor response to first-line
therapy, suggesting poorer overall health at
baseline. Two patients died, both from pro-
gressive heart failure; moreover, both were
in WHO functional class IV at the begin-
ning of the study period. Additionally,
more patients in the switch and added
groups required hospitalization and the
addition of diuretic treatment; this may
also have been because these patients had
poorer overall health at baseline; however,
we cannot rule out that these effects may
have been directly caused by macitentan.
Finally, this was not a randomized study;
thus, the highly heterogeneous patient
groups were not directly comparable at
baseline. However, this study reflects real-
life situations, in that clinicians often
encounter difficulty with regard to manage-
ment of disease in patients with suboptimal
response to therapy. Importantly, however,
we have shown that in a group of patients
with poorly controlled PAH on existing
ERA regimens, switching to a plausibly
more effective ERA (macitentan) may facil-
itate clinically meaningful improvements.
In summary, we found a significant
improvement in WHO functional class
and 6MWT in patients who switched from
bosentan/ambrisentan to macitentan. To
our knowledge, this has not been previously
studied. We believe that the strength of this
study is that the parameters used in the
study are equivalent to those routinely
used in clinical practice, such that they are
available when determining the course of
treatment in patients with PAH. Switching
from bosentan or ambrisentan to maciten-
tan is a therapeutic option available to clini-
cians who treat patients with suboptimal
response to therapy for PAH.
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